Abstract 1813MO
Background
Cancer cachexia, characterized by systemic inflammation and muscle wasting, have been associated with poor survival in non-small-cell lung cancer (NSCLC) patients (pts). We hypothesized whether neutrophil-to-lymphocyte ratio (NLR) and the intramuscular adipose tissue/skeletal muscle index (IMAC/SMI) are associated with prognosis in metastatic NSCLC (mNSCLC). We also considered the quality of life (QoL) assessed via the EORTC-QLQ-CAX24 questionnaire on the prognosis of mNSCLC.
Methods
We analyzed a prospective cohort study (Apr/2017 to May/2020) of pts diagnosed with histologically-proven, treatment-naive, mNSCLC. After signed informed consent, we evaluated pts about demographic features and QoL using the EORTC-QLQ-C30 and -CAX24 scales. We used the baseline NLR as a surrogate of systemic inflammation. IMAC/SMI was evaluated using baseline plain computed tomography imaging at the third lumbar vertebra level. To test our hypothesis that NLR and IMAC/SMI are associated with prognosis, we carried out a Cox multivariate regression and included age, gender, ECOG-PS, and histology as covariates.
Results
We collected 128 pts, median age 65 y.o. (23-86), 79 (62%) male. Lung adenocarcinoma was the predominant histology (66%). ECOG-PS was classified as 0-1 in 27 pts (21%) and 2-4 in 101 pts (79%). Median overall survival was 468, 335, 106, 59, and 20 days in pts with ECOG-PS 0, 1, 2, 3, and 4, respectively. Elevated NLR (Hazard ratio (HR) = 1.26, 95% confidence interval (CI) = [1.01 - 1.59], p=0.038), IMAC/SMI ratio (HR = 1.37, 95% CI = [1.03 - 1.84], p=0.032), and CAX24 score for food aversion (HR = 1.52, 95% CI = [1.13 - 2.03], p=0.006) were associated with worse prognosis in mNSCLC. Indeed, higher ECOG-PS (Spearman rho=0.208, p=0.027), CAX24 scores for food aversion (rho=0.197, p=0.036), loss of control (rho=0.212, p=0.024), and eating and weight loss worry domains (rho=0.219, p=0.020) were associated with elevated NLR levels.
Conclusions
Elevated NLR, IMAC/SMA ratio, and CAX24 score for food aversion are independently associated with worse survival in mNSCLC. These data underscore the importance of cachexia features as negative prognostic factors in mNSCLC.
Clinical trial identification
NCT03960034.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP grants 2015/22814-5 and 2016/20187-6.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1811MO - Association of pre-existing cardiovascular disease (CVD) in older patients with breast cancer with treatment and survival outcomes
Presenter: Atul Batra
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1812MO - Effects of oncologic rehabilitation during adjuvant endocrine therapy in overweight or obese patients with breast cancer
Presenter: Harm Ormel
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1505MO - Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic
Presenter: Deniz Can Guven
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1814MO - Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: A randomized, open-label trial
Presenter: Atul Sharma
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1815MO - Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial
Presenter: Luigi Celio
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1816MO - ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy – with a focus on nausea. MASCC Antiemetic Study Group survey
Presenter: Teresa Smit
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1817MO - Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)
Presenter: Pietro Lapidari
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1818MO - Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? Intermediate results from the MeTHOS study
Presenter: Spyros Xynogalos
Session: Mini Oral - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Gudrun Kreye
Session: Mini Oral - Supportive and palliative care
Resources:
Webcast
Invited Discussant 1811MO, 1812MO, 1505MO and 1813MO
Presenter: Anton Snegovoy
Session: Mini Oral - Supportive and palliative care
Resources:
Slides
Webcast